DALLAS, May 6, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Genetic Technologies Ltd. (ADR) (Nasdaq:GENE). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: www.microstockprofit.com/lp/GENE
Genetic Technologies (GENE) is a leading-edge genetic testing business, which, together with an extensive range of international patents and allied research activities, aims at uncovering the impact of DNA (Deoxyribonucleic Acid) on health. The Company was an early pioneer in recognizing important new applications for "non-coding" DNA. It has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all species. Its business strategy is the global commercialization of its patents through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics portfolio.
This newsletter has been helping traders make great investment decisions on GENE; click here for a 25% discount offer.
In the report, the analyst notes:
"GENE gained 2.88% to close Thursday at $7.50, a day after shares corrected to $7.29 following last week's price and high volume run up. The Australian biotech firm's shares have been on the rise since it reported on April 26 that it secured U.S. approval for the launch of BREVAGen breast cancer risk test."
"GENE is about to complete the launch preparations for BREVAGen, and it expects to offer the breast cancer risk test to U.S. physicians and their patients in coming weeks. The Company anticipates the test to be available to European and PacRim markets once all the regulatory and market development programs are complete."
To read the entire report visit: www.microstockprofit.com/lp/GENE
See what investors are saying about GENE at http://www.stockhideout.com
Get breaking news on GENE at http://thestockmarketwatch.com/
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.